New combo tackles relapsed blood cancers after transplant

NCT ID NCT05226455

Ongoing Disease control Sponsor: Groupe Francophone des Myelodysplasies Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in 55 adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that returned after a stem cell transplant. The goal is to find the best dose and see if the treatment can improve outcomes. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax (Venclyxto) and azacitidine (Vidaza) with or without donor lymphocyte infusion
What this could lead to: If successful, this combination could offer a new treatment option for patients whose MDS or AML returns after a stem cell transplant.
What could go wrong: This is an early phase I-II study with only 55 participants, so results are preliminary. The drugs can cause serious side effects, and the donor cells may attack the patient's body (graft-versus-host disease).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML MDS

Contacts and locations

Locations

CHU Hôtel Dieu

Nantes, 44093, France
CHU d'Angers

Angers, 49933, France
CHU de Grenoble

Grenoble, 38043, France
CHU de Haut-Lévèque

Pessac, 33604, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Hospitalier Lyon-Sud

Pierre-Bénite, 69495, France
Hôpital Dupuytren

Limoges, 87042, France
Hôpital Saint louis

Paris, 75010, France
Hôpital Saint-Eloi

Montpellier, 34295, France
Hôpital l'Archet I

Nice, 06200, France
IUCT Oncopole

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.